Recent FDA Approvals Continue to Focus on Targeted and Immunotherapy

Kathleen Wiley, RN, MSN, AOCNS®


Oncology clinicians can expect to continue to see new targeted and immunotherapy drugs emerge as clinically approved agents in the fight against cancer.

Five cancer-related U.S. Food and Drug Administration (FDA) approvals occurred in the first quarter of 2017; following are their indications for treatment and associated clinical implications. (Refer to the package inserts to guarantee the most recent dosing and drug information.) You’ll recognize that some of the agents were already FDA approved for other uses, but as clinical trials continue and new data emerge, clinical use is expanding to other disease sites and indications.

View Article @

ONS Articles

Dive into a rich source of oncology nursing expertise with ONS articles.

View All Articles